Loading...
XNAS
PTGX
Market cap3.29bUSD
Jul 11, Last price  
53.00USD
1D
0.32%
1Q
24.35%
Jan 2017
141.02%
IPO
358.08%
Name

Protagonist Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
11.94
P/S
7.56
EPS
4.44
Div Yield, %
Shrs. gr., 5y
20.24%
Rev. gr., 5y
351.71%
Revenues
434m
+624.06%
00020,063,00030,925,000231,00028,628,00027,357,00026,581,00060,000,000434,433,000
Net income
275m
P
-11,072,000-14,858,000-37,177,000-36,957,000-38,924,000-77,187,000-66,150,000-122,627,000-123,413,000-78,955,000275,188,000
CFO
184m
P
-7,743,000-14,385,000-29,972,0003,872,000-49,947,000-41,527,000-72,484,000-107,865,000-108,137,000-70,236,000184,152,000
Earnings
Aug 04, 2025

Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
IPO date
Aug 11, 2016
Employees
106
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
434,433
624.06%
60,000
125.73%
26,581
-2.84%
Cost of revenue
181,590
153,652
158,986
Unusual Expense (Income)
NOPBT
252,843
(93,652)
(132,405)
NOPBT Margin
58.20%
Operating Taxes
4,220
(3,980)
Tax Rate
1.67%
NOPAT
248,623
(93,652)
(128,425)
Net income
275,188
-448.54%
(78,955)
-36.02%
(123,413)
0.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
132,100
18,838
BB yield
-10.15%
-3.52%
Debt
Debt current
510
2,282
2,515
Long-term debt
21,222
1,141
4,797
Deferred revenue
Other long-term liabilities
11,676
(221)
783,542
Net debt
(397,181)
(338,194)
(230,268)
Cash flow
Cash from operating activities
184,152
(70,236)
(108,137)
CAPEX
(1,355)
(609)
(795)
Cash from investing activities
(299,483)
(39,258)
91,468
Cash from financing activities
25,853
170,477
18,838
FCF
109,636
(91,175)
(126,317)
Balance
Cash
418,913
341,617
237,355
Long term investments
225
Excess cash
397,191
338,617
236,251
Stockholders' equity
(340,603)
(615,814)
(537,114)
Invested Capital
1,038,440
954,552
756,378
ROIC
24.95%
ROCE
36.23%
EV
Common stock shares outstanding
65,078
56,764
49,042
Price
38.60
68.34%
22.93
110.17%
10.91
-68.10%
Market cap
2,512,000
92.99%
1,301,588
143.26%
535,051
-66.23%
EV
2,114,819
963,394
304,783
EBITDA
255,738
(90,340)
(129,036)
EV/EBITDA
8.27
Interest
3,369
Interest/NOPBT